Variable | Categorization | Overall survival | Disease-free survival | ||||
---|---|---|---|---|---|---|---|
n1 | events | P 2 | n1 | events | P 2 | ||
Clinicopathological factors | |||||||
Age at diagnosis | |||||||
<57 years | 64 | 7 | 0.094 | 64 | 16 | 0.711 | |
≥ 57 years | 61 | 14 | 61 | 14 | |||
Tumor size3 | |||||||
pT1-pT2 | 107 | 17 | 0.372 | 107 | 25 | 0.427 | |
pT3-pT4 | 16 | 4 | 16 | 5 | |||
Lymph node status3 | |||||||
pN0 | 54 | 3 | 0.002 | 54 | 5 | <0.001 | |
pN1-pN3 | 65 | 18 | 65 | 24 | |||
Histological grade | |||||||
G1-G2 | 72 | 5 | 0.001 | 72 | 11 | 0.012 | |
G3 | 53 | 16 | 53 | 19 | |||
Histological type | |||||||
IDC | 101 | 19 | 0.267 | 101 | 22 | 0.277 | |
other | 24 | 2 | 24 | 8 | |||
Immunohistochemistry | |||||||
Estrogen receptor | |||||||
negative (IRS4 0–2) | 40 | 9 | 0.155 | 40 | 9 | 0.962 | |
positive (IRS 3–12) | 80 | 12 | 80 | 21 | |||
Progesterone receptor | |||||||
negative (IRS4 0–2) | 39 | 9 | 0.154 | 39 | 13 | 0.087 | |
positive (IRS 3–12) | 81 | 12 | 81 | 17 | |||
WIF1 promoter | |||||||
unmethylated | 47 | 9 | 0.656 | 47 | 8 | 0.154 | |
methylated | 78 | 12 | 78 | 22 | |||
DKK3 promoter | |||||||
unmethylated | 46 | 1 | <0.001 | 46 | 7 | 0.037 | |
methylated | 79 | 20 | 79 | 23 |